Conference Coverage

CKD triples risk of bad outcomes in HIV


 

REPORTING FROM CROI


The subjects were all participants in the D:A:D project [Data Collection on Adverse Events of Anti-HIV Drugs], an ongoing international cohort study based at the University of Copenhagen, and funded by pharmaceutical companies, among others.

Dr. Ryom had no disclosures.

SOURCE: Ryom L et al. CROI, Abstract 75.

Pages

Recommended Reading

Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief
MDedge Family Medicine
Comorbidity occurs earlier and more commonly with HIV infection
MDedge Family Medicine
Antiretroviral choice for pregnant women with HIV does not appear to impact birth outcomes
MDedge Family Medicine
HIV infection linked to higher risk of non-melanoma skin cancer
MDedge Family Medicine
Most HIV patients need treatment for acute HCV
MDedge Family Medicine
Emotional regulation training lowers risk of adolescents having sex
MDedge Family Medicine
FDA seeks comments on pediatric HIV product development
MDedge Family Medicine
FDA approves epoetin alfa biosimilar to treat anemia
MDedge Family Medicine
FDA: PrEP indication updated to include adolescents at risk of HIV infection
MDedge Family Medicine
FDA warns of birth defect risks from dolutegravir
MDedge Family Medicine